At Novonesis, we believe solutions rooted in biology are key to tackling the challenges our world faces. Enzymes, functional proteins and microorganisms are our planet's tiniest, yet mightiest agents of change. When we leverage their power with science, we create biosolutions that transform the way we all produce, consume and live. Today, we are 10,000 people worldwide whose expertise spans more than 30 different industries. All around the world our biosolutions already create value for thousands of customers and benefit the planet. Our solutions enable feeding and fueling the world more sustainably, from healthy and sustainable nutrition to biofuel. Biosolutions also reduce the use of fossil-based resources, chemicals, energy and water. And this is just the beginning. The potential is almost endless. The time for biosolutions is now. And by working closely with our partners and customers, we will continue to challenge conventional thinking and transform business with biology. Together, we will create the change our world needs. Let’s better our world with biology.

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. As one of the top 5 agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. With a presence in more than 130 countries and more than 10,000 colleagues globally, we reach more than 90% of the world’s food basket. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com.

Marken is the clinical and advanced therapy subsidiary of UPS Healthcare. With Marken, Polar Speed and BOMI Group included, the UPS Healthcare network consists of 200+ locations worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 60 locations worldwide, while maintaining the leading position for cell and gene therapy services, direct-to-patient and home healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 2,600+ staff members manage 180,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 16,000+ home healthcare visits. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry. Delivering What Matters From Clinical to Commercial.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Engineered to perform Qualicaps® is a global manufacturer of empty pharmaceutical capsules and pharmaceutical processing equipment. With more than 100 years of experience, Qualicaps is a leader in innovation in both Quali-G™ (gelatin) and Quali-V® (hypromellose) capsules, and offers a proprietary product line of pharmaceutical equipment, including capsule filling, band-sealing and inspection machinery. For more information visit www.qualicaps.com.

Drake Extrusion is North America’s leading manufacturer of colored filament yarn and staple fiber. For over two decades, the name Drake has led the colored polypropylene fiber industry in North America, with research and development based on two continents. Our sister companies IFG Drake, IFG Asota and IFG Exelto have advanced development in high-performance fibers. Located in North America’s textile heartland, we have an unrivaled reputation for excellent customer service, and offer you the personalized service and flexibility of a custom supplier, backed by the resources of our parent company, International Fibres Group. Markets we serve, but are not limited to, are: - Automotive - Home Furnishings - Floor Coverings - GeoTextile - Specialty/Niche Markets

Brii Biosciences is a commercial stage biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

As a medium sized, family-owned company in its second generation we are known internationally as a "Specialist for Macromolecular Chemistry"​. Starting with the development of polymer dispersions for adhesives, our core business, today, is the development, production, and marketing of polymers in the form of emulsions, solutions, or as mass polymers.

Connecting the global textile community to empower an innovative, informed, and sustainable future Responsibility for the content and opinions expressed in shared or reposted content is that of the original author or organization, and not of AATCC. Mention of any trade name or proprietary product in these posts does not constitute a guarantee or warranty of the product by AATCC and does not imply its approval to the exclusion of other products that may also be suitable

We’re on a mission to protect the planet from the cost of clothing. At Circ, we’ve created a technology system that returns clothes to the raw materials from which they were made. Again and again. Brand partners like Patagonia, Marubeni, and Fashion For Good are joining us in our goal of turning wasteful fashion lines into renewable fashion circles. By 2030, we expect to have recycled 10 billion garments, represent 10% of the global apparel market, and to have saved more than 100 million trees. As our ecology and economy grow evermore entwined, it is clear to us that the world already has all the clothing it needs to create all the clothing it will ever need. Join us in threading together the future of circular fashion and eliminating our collective fashion footprint.

Andersen Products distributes and services gas sterilization products manufactured by Andersen Sterilizers, Inc. Andersen Products was founded in 1958. It began its medical business in Oyster Bay, New York in 1963 with the manufacture of a new design for a stomach tube. The need to sterilize these tubes led to the development of the Anprolene line of ethylene oxide sterilizers. Today the product line includes two lines of gas sterilizers (Anprolene and EOGas), with their associated chemical and biological sterilization monitors as well as gastric sump tubes, wound drains and pumps, and thoracic pumps. Andersen customers include a diverse group of over 6,000 healthcare-related facilities around the world, such as hospitals, day surgery centers, veterinary clinics, research and clinical laboratories, and other medical device manufacturers. Andersen conducts business with distributors in every continent and subcontinent. From mobile field hospitals in developing countries to the most sophisticated tertiary care institutions on the globe — Andersen is there. The company was founded by Dr. Harold W. Andersen, a surgeon from New York. Dr. Andersen invented a better apparatus for gastric drainage in the course of his clinical work at Bellevue Hospital in New York City. His colleagues began asking for the new devices, which led to the formation of Andersen Products. Over the years, the company has maintained its focus on providing cutting-edge technology for niche healthcare applications, and in particular for those related to sensitive instrument sterilization. Health Science Park, the group's North Carolina headquarters, houses manufacturing, quality assurance laboratory, R&D, warehousing, sales/marketing and administrative offices. The plant is EPA- and FDA-registered, and OSHA compliant.

Yukon Medical designs innovative products that simplify drug reconstitution and medication delivery, increase caregiver safety, and address complex challenges using novel approaches. These include our Vialok® Non-Vented Vial Access devices, Vialok® Vented Vial Access devices, Arisure™ Closed Medication System, and our Advanced Reconstitution Systems. Additional products currently in development will expand our future offerings.